Sign In
Buy GILD
$125.16
+0.110 (+0.0880%)
At Close: Jun 24, 2026
4%-Yielding Gilead Sciences' Potential Path To A $100 Stock Price
03:37pm, Wednesday, 15'th Nov 2023
Gilead Sciences has a robust pipeline in oncology and HIV, indicating sustained growth potential. The company offers dividends, buybacks, and an attractive valuation, making it an appealing investment
Arcellx stock climbs on Gilead investment
11:03am, Wednesday, 15'th Nov 2023
Arcellx Inc (NASDAQ:ACLX) shares jumped 8% to $51.28 in early Wednesday trading after the clinical-stage biotechnology company announced that it has received a $200 million equity investment from Gile
Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium
06:23am, Wednesday, 15'th Nov 2023
Shares of Arcellx Inc. ACLX, +4.33% were set to surge Wednesday, after biotechnology company announced a $200 million equity investment by Gilead Sciences Inc.'s GILD, -0.28% Kite as part of an expand
5 Dirt-Cheap Healthcare Stocks With Big Dividends To Buy Now
01:10pm, Saturday, 11'th Nov 2023
While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of 2023 and li
WHO's new COVID guidelines see fewer patients requiring hospitalization
08:43am, Friday, 10'th Nov 2023
Most patients are unlikely to develop severe disease or die if they get the current variants of COVID-19 as immunity levels have climbed given higher levels of vaccination.
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
08:16am, Thursday, 09'th Nov 2023
Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.
Buying the dip in high-yield Gilead Sciences
06:10am, Thursday, 09'th Nov 2023
Gilead Sciences NASDAQ: GILD share price tanked following the Q3 release on what was otherwise a good report. The company is gaining traction in key markets, sustaining its core business, and offsetti
Gilead Sciences to Present at Upcoming Investor Conferences
07:13pm, Wednesday, 08'th Nov 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Healthca
Gilead Sciences, Inc. (GILD) Q3 2023 Earnings Call Transcript
08:42pm, Tuesday, 07'th Nov 2023
Gilead Sciences, Inc. (NASDAQ:GILD ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chi
After-Hours Selling to Challenge Winning Streak Wednesday
07:32pm, Tuesday, 07'th Nov 2023
Gilead, eBay and Rivian all beat on the bottom line in Q3, but all three are selling the news.
Compared to Estimates, Gilead (GILD) Q3 Earnings: A Look at Key Metrics
07:32pm, Tuesday, 07'th Nov 2023
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estim
Gilead Sciences (GILD) Tops Q3 Earnings and Revenue Estimates
06:47pm, Tuesday, 07'th Nov 2023
Gilead Sciences (GILD) came out with quarterly earnings of $2.29 per share, beating the Zacks Consensus Estimate of $1.91 per share. This compares to earnings of $1.90 per share a year ago.
Gilead Sciences 3Q results top estimates on cancer and HIV drug sales
04:51pm, Tuesday, 07'th Nov 2023
Gilead Sciences Inc after Tuesday's close announced third quarter 2023 adjusted earnings per share (EPS) of $2.29, surpassing the analyst consensus forecast of $1.91, according to Zacks Equity Researc
Gilead stock rises on top-, bottom-line beats
04:09pm, Tuesday, 07'th Nov 2023
Gilead Sciences Inc.'s GILD, -0.65% stock climbed 2% in extended trading Tuesday after the pharmaceutical company reported quarterly results that topped analyst revenue and earnings estimates. Gilead
Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More
09:47am, Monday, 06'th Nov 2023
Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.
